Long-Acting Injectables for Parenteral Use
DelSiTech has developed long-acting formulations enabling slow release of therapeutic drugs, with adjustable release durations ranging from 24 hours to 12 months. The key advantages of the DelSiTech Silica Matrix include the following:
1) A versatile platform:
DelSiTech’s biodegradable silica-based technology provides a flexible solution for the drug delivery and the protection of
-
- small peptides
- peptides
- large biologics.
- vaccine: proteins, mRNAs, liposomes, LNPs and adjuvants
2) Adjustable controlled release:
The release rate is governed by the silica biodegradation process, which can enable a predictable and sustained release profile. This erosion-based mechanism allows:
-
- near zero-order release kinetics
- reduced to no initial burst release
- controlled release across a variety of drug properties, including solubility, molar mass, and diffusivity
3) Protection of sensitive molecules:
The technology is designed to help maintain the chemical stability and biological activity of sensitive drug substances by shielding them from external conditions prior to release. This is achieved through:
-
- encapsulation of the drug in solid silica microparticles
- prevention of diffusion and limited exposure to external pH, enzymes, or oxidation before release
- silica inorganic chemistry is mainly inert with organic compounds
These features can be particularly beneficial for the delivery of large biological macromolecules such as proteins, monoclonal antibodies, and RNA, where conventional delivery methods often face limitations.
